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T lymphocytes play an essential role in the defense
against several pathogens and in tumor immune surveil-
lance. However, T cells can also trigger autoimmune
diseases and acute allograft rejection. Therefore, under-
standing the mechanisms of activation of T lymphocytes
may help develop novel immunomodulators for thera-
peutic purposes.
T-cell activation results from recognition by the T-cell
receptor of a specific antigenic peptide within a specific
major histocompatibility complex molecule expressed on
antigen-presenting cells (APCs). In addition, naı¨ve T cells
express the costimulatory receptor CD28 that binds lig-
ands also expressed on APCs. Coengagement of at least
T-cell receptor and CD28 is necessary for naı¨ve T cells
to undergo activation, proliferation, and differentiation.
Upon activation, T cells transiently up-regulate a number
of alternative costimulatory receptors [1]. In addition, re-
cently activated T cells also express inhibitory receptors
such as CTLA-4 [2], PD-1, BTLA, and Fas, the engage-
ment of which may lead to cell-cycle arrest or apoptosis
and limits the magnitude and/or duration of an immune
response. Mice carrying null mutations of these inhibitory
genes all develop different degrees of lymphoaccumula-
tion and autoimmunity.
The ratio of surface versus intracellular expression of
CTLA-4, which determines how much CTLA-4 can bind
its ligand, is regulated by the phosphorylation status of a
tyrosine in its cytoplasmic tail [3–5]. Functionally, CTLA-
4 appears to regulate the threshold of T-cell activation, as
CTLA-4–deficient T cells require lower levels of anti-
genic stimulation than CTLA-4 expressing T cells [6].
In addition, the inhibitory effect of CTLA-4 appears to
be greater in secondary than in primary stimulation of
naı¨ve T cells [6]. We have used several approaches cen-
tered on CTLA-4 to inhibit immune responses in vivo.
First, targeted cross-linking of CTLA-4 using membrane-
bound single-chain anti-CTLA-4 antibody expressed on
C© 2004 by the International Society of Nephrology
allogeneic cells effectively down-regulated allograft de-
struction in a mouse model in vivo [7]. Conversely, trans-
genically driven constitutive expression of CTLA-4 on
T cells significantly delayed acute allograft rejection as
well as dramatically reduced disease in an experimen-
tal model of autoimmunity (manuscript in preparation).
However, the mechanisms by which CTLA-4 inhibits
T-cell responses are not completely understood. Collec-
tive evidence from different laboratories suggests that
CTLA-4 engagement may not only directly inhibit acti-
vation of conventional T cells, but also reduce the func-
tion of ligand-expressing APCs, and perhaps play a role in
the suppressor function of a subset of regulatory T cells.
These latter properties may, indirectly, also reduce the
function of conventional T cells.
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